Suzetrigine (Journavx-suzetrigine): First-in-Class, Non-Opioid Pain Treatment
Suzetrigine, marketed as Journavx, is a first-in-class, oral, non-opioid analgesic, officially approved by the FDA on January 30, 2025 for treating moderate-to-severe acute pain in adults. It fills a long-standing void—being the first new non-opioid pain medication approved in over 20 years.